三金脑脉泰在血管性痴呆治疗中的应用效果观察

Effect of Sanjin Naomaitai in Treatment of Vascular Dementia

目的:探讨三金脑脉泰治疗血管性痴呆的临床效果。方法:2020年4月-2021年4月上海市徐汇区中心医院收治的血管性痴呆患者50例,随机分为两组,各25例。对照组采用安慰剂胶囊+甲磺酸双氢麦角毒碱片治疗;研究组采用安慰剂片+三金脑脉泰胶囊治疗。比较两组治疗效果。结果:两组智能及行为能力的治疗总有效率比较,差异无统计学意义(P>0.05);研究组治疗后简易精神状态量表评分及P300波幅水平均高于对照组,P300潜伏期水平低于对照组,差异有统计学意义(P<0.05)。结论:采用三金脑脉泰治疗血管性痴呆的精神状态较甲磺酸双氢麦角毒碱片好,但临床疗效无较大区别,药物使用后不会导致较为严重的不良反应。

Objective:To explore the effect of Sanjin Naomaitai in the treatment of vascular dementia.Methods:From April 2020 to April 2021,50 patients with vascular dementia who were admitted to the Central Hospital of Xuhui District of Shanghai City were randomly divided into two groups with 25 cases in each group.The control group was treated with placebo capsule plus Dihydroergotoxin Mesylate Tablets.The study group was treated with placebo tablets plus Sanjin Naomaitai Capsule.The therapeutic effects of the two groups were compared.Results:There was no significant difference in the total effective rate of intelligence and behavioral ability between the two groups(P>0.05).In the study group after treatment,mini-mental state examination scale score and P300 amplitude level were higher than those in the control group,and P300 latency level was lower than that in the control group,the difference was statistically significant(P<0.05).Conclusion:In treatment of vascular dementia,Sanjin Naomaitai achieves better mental state than Dihydroergotoxine Mesylate Tablets,but the clinical efficacy shows insignificant difference,and the use of drugs may not lead to relatively serious adverse reactions.